Neorx Corporation

Aletheon Pharmaceuticals, Inc.

Scott Stoll Graves

John M Reno

Alan R Fritzberg

Sudhakar Kasina

Paul G Abrams

Donald B Axworthy

Mark D Hylarides

James A Sanderson

Robert W Mallett

Stephen M J Searle

Stephen Charles Goshorn

Anthony R Rees

Andrew H Henry

Joanne Elaine Schultz

Jan T Pedersen

Yukang Lin

The present invention provides vectors for expressing genomic streptavidin fusion cassettes. In the various embodiments, fusion proteins produced from these vectors are provided. In particular embodiments, fusion proteins comprising a single chain antibody and genomic streptavidin are provided as are vectors encoding the same. Also provided, are methods of using the fusion proteins of the present invention, and in particular, the use of scFvSA fusion proteins as diagnostic markers or as a cell specific targeting agents.

Streptavidin expressed gene fusions and methods of use thereof

Humanized antibodies which bind the NR-LU-13 antigen, conjugates containing such antibodies, and their use in pretargeting methods and conventional antibody therapy and immunodiagnosis are provided.

Humanized antibodies that bind to the antigen bound by antibody NR-LU-13

Methods for targeting cytotoxins to target sites by administration of a combination of conjugates are provided. Novel cytotoxic combinations for use in such methods are also provided.

Pretargeting protocols for the enhanced localization of cytotoxins to

Growing community of inventors

Monroe, WA, United States of America

Scott Stoll Graves